Journey Medical Corporation (NASDAQ:DERM), currently valued at $148.63 million, will be added to the Russell 2000 and Russell 3000 indexes effective after U.S. markets close on June 27, 2025, the company announced Tuesday.
The dermatology-focused pharmaceutical company, which markets FDA-approved prescription medications for skin conditions, expects the inclusion to enhance its visibility among investors and institutions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.